Which of the following statements regarding ticlopidine is TRUE?
**Question:** Which of the following statements regarding ticlopidine is TRUE?
A. Ticlopidine is a platelet aggregation inhibitor
B. Ticlopidine is a calcium channel blocker
C. Ticlopidine is an antihistamine
D. Ticlopidine is a beta-blocker
**Core Concept:** Ticlopidine is a medication primarily used to prevent thrombosis and reduce the risk of stroke and myocardial infarction in patients with peripheral artery disease or peripheral vascular disease. It works by inhibiting platelet aggregation, preventing the formation of blood clots.
**Why the Correct Answer is Right:** Ticlopidine is a thienopyridine class drug that specifically inhibits the P2Y12 receptor on platelets, leading to a decrease in adenosine diphosphate (ADP) and adenosine monophosphate (AMP) receptor stimulation. This results in a decrease in platelet aggregation and ultimately reduces the risk of thrombotic events.
**Why Each Wrong Option is Incorrect:**
A. Ticlopidine is not a calcium channel blocker; calcium channel blockers, such as nifedipine and verapamil, work by inhibiting calcium influx into cells, which helps in the treatment of hypertension, angina, and migraine.
B. Ticlopidine is not an antihistamine, which are medications that primarily block histamine receptors, typically used to treat allergies, hay fever, and motion sickness.
C. Ticlopidine is not an antihistamine; antihistamines, such as cetirizine and loratadine, work by blocking histamine H1 receptors, leading to the relief of allergic symptoms.
D. Ticlopidine is not a beta-blocker, which are medications used to lower heart rate and blood pressure, treat angina, and prevent heart attacks. Beta-blockers, such as propranolol and atenolol, work by blocking beta-adrenergic receptors, reducing heart rate and cardiac contractility.
**Clinical Pearl:** Ticlopidine is a useful medication in preventing thrombotic events, particularly in patients with peripheral artery disease or peripheral vascular disease, where it helps to reduce the risk of stroke and myocardial infarction. However, it is associated with an increased risk of severe thrombocytopenia, which is a decrease in the number of platelets in the bloodstream, leading to an increased risk of bleeding complications. This side effect is why the newer thienopyridine derivative, clopidogrel, has largely replaced ticlopidine in many clinical settings, as it has a lower risk of thrombocytopenia.